info@ehidc.org

 202-624-3270

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate

The Company is in ongoing discussions with many stakeholders, including national governments and global organizations, as part of its efforts to meet its commitment to make the vaccine candidate accessible globally, provided the vaccine is demonstrated to be safe and effective and following regulatory approval.

External News Article: 
Add reference to external site news article
News Category: 
Member News